FHA
VNDA icon

First Horizon Advisors’s Vanda Pharmaceuticals VNDA Stock Holding History

First Horizon Advisors’s Portfolio VNDA Stock Details VNDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-779
Closed -$9K – 2560
2022
Q1 		$9K Buy
+779
New +$10.2K ﹤0.01% 1148

Other funds holding VNDA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
EIP
Epoch Investment Partners New York $16.5B AUM 24.3% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

First Horizon Advisors's VNDA Position: Q2 2022 in Review

First Horizon Advisors sold out of Vanda Pharmaceuticals (VNDA) in Q2 2022, closing a stake of 779 shares — an estimated $9K sold.

First Horizon Advisors first reported a position in VNDA in Q1 2022 and held it in 1 quarter. The position peaked at $9K in Q1 2022. 173 funds tracked by Wall St. Rank hold VNDA as of Q2 2022.

  • First Horizon Advisors reported no remaining Vanda Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
  • First Horizon Advisors sold 779 Vanda Pharmaceuticals shares in Q2 2022, an estimated $9K.
  • First Horizon Advisors first reported a position in Vanda Pharmaceuticals in Q1 2022 and held it in 1 quarter.
  • First Horizon Advisors's Vanda Pharmaceuticals position peaked at $9K in Q1 2022.
  • 173 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q2 2022.

Based on First Horizon Advisors's 13F filing for Q2 2022, filed 2 Aug 2022.